Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
European Journal of Haematology|November 29, 2016
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myelomaMassimo Offidani, Laura Corvatta, Sara Bringhen, et al.
Cancer|June 28, 2007
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapyAntonio Palumbo, Sara Bringhen, Patrizia Falco, et al.
Haematologica|September 4, 2025
Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled webGiuseppe Bertuglia, Enrico Amaducci, Davide Stella, et al.
Nature Reviews. Disease Primers|July 21, 2017
Multiple myelomaShaji K Kumar, Vincent Rajkumar, Robert A Kyle, et al.
Cancers|April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple MyelomaKatia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers|August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Annals of Hematology|January 8, 2025
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Journal of Clinical Medicine|September 30, 2020
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple MyelomaMaría-Victoria Mateos, Joan Bladé, Sara Bringhen, et al.
Leukemia & Lymphoma|November 21, 2008
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonatesVittorio Montefusco, Francesca Gay, Francesco Spina, et al.
Oncotargets and Therapy|September 3, 2025
The Role of CELMoD Agents in Multiple MyelomaNiels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
European Journal of Haematology|November 29, 2016
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myelomaMassimo Offidani, Laura Corvatta, Sara Bringhen, et al.
Cancer|June 28, 2007
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapyAntonio Palumbo, Sara Bringhen, Patrizia Falco, et al.
Haematologica|September 4, 2025
Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled webGiuseppe Bertuglia, Enrico Amaducci, Davide Stella, et al.
Nature Reviews. Disease Primers|July 21, 2017
Multiple myelomaShaji K Kumar, Vincent Rajkumar, Robert A Kyle, et al.
Cancers|April 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple MyelomaKatia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Cancers|August 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168Katia Mancuso, Simona Barbato, Francesco Di Raimondo, et al.
Annals of Hematology|January 8, 2025
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodiesLuciano J Costa, Francesca Gay, Ola Landgren, et al.
Journal of Clinical Medicine|September 30, 2020
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple MyelomaMaría-Victoria Mateos, Joan Bladé, Sara Bringhen, et al.
Leukemia & Lymphoma|November 21, 2008
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonatesVittorio Montefusco, Francesca Gay, Francesco Spina, et al.
Oncotargets and Therapy|September 3, 2025
The Role of CELMoD Agents in Multiple MyelomaNiels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Pageof 18